Marketers. Where's The Paper?

Many marketing managers tell me the same thing: the technology is great, the science is strong, and they have all the evidence to back it up. Yet, scientists are unaware, and campaigns get little engagement. 

I ask them one question every single time: where's the paper?

An awkward silence usually follows. Then an explanation of why there isn't one yet.

Facts are not considered true in science until they're published. That sounds obvious when you say it about research. Your marketing claims follow exactly the same rule, whether you like it or not.

A scientist doesn't read your whitepaper the way everyone else does

A marketing director reads a claim and asks if it sounds credible. A scientist reads the same claim and asks one thing: where's the data. Not the summary. Not the nicely designed case study wrapped around it. The method, the result, the peer review that proves someone other than you checked the work.

This isn't a preference. It's wired into how we are trained. I spent my PhD years learning that a claim without evidence is worthless, and that the only way to make something stick is to hand it to people actively trying to break it (usually reviewer 2). Put an unproven performance claim on a product page in front of that person and you're asking them to throw away the one principle they've built their entire career on.

So when your content reads like assertion dressed up as fact, a scientific buyer doesn't quietly scroll past. They clock it immediately. And once a scientist decides your company doesn't play by their rules, that verdict is nearly impossible to reverse.

The company that never had to make this argument

Story time. I worked with Curio Bioscience on their early content, before their acquisition, and got to sit down with one of their founding team, Dr. Sam Rodriguez, who incidentally was working in the same institute during my PhD.

Curio as a company didn't start with a business or marketing plan. It started with a couple of published papers from a PhD program.

Spatial transcriptomics research and a cool technology, published in Science and then Nature Biotechnology, pulled over 100,000 views and downloads instantly.

That paper alone did more for the company's visibility, credibility, and fundraising than any campaign ever could. Scientists in the field knew and wanted the technology before Curio had hired a single marketing person. Within a few years, Takara Bio acquired them.

Don't confuse it as luck. Curio proved the science first and let the marketing catch up. Most companies still do it backwards, and then wonder why nobody believes them.

Marketing teams are scared of the wrong thing

Most marketing leads avoid the publication route because it feels foreign. It's not their job, they haven't done it, it looks slow and academic, and it seems miles away from a launch calendar. It isn't, once someone actually sits with your existing data and asks what's publishable.

And what they dont realise, most established life science companies already have tons of results sitting in a folder good enough to hold up under review. Nobody has ever looked at them and asked "is this a paper", because the scientific team is too busy doing the science to write about it and it's not a direct role responsibility.

That's the entire gap. Not weak results. Nobody treating the data as an asset.

This is exactly why an external scientific writing partner moves faster than either team expects. Someone whose actual job is to interrogate the data, spot the result that matters, and carry it through submission kills the excuse that's been sitting there for years: we'll get to it eventually.

Go and check your own folder

Stop drafting the next whitepaper for a minute. Go and ask your scientific team one question: what result do we have that nobody outside this building has ever seen?

Not the polished internal deck. The raw finding that's never been near a reviewer.

If the answer really is nothing, fine, at least you know where you stand - but your science team better get to work. But in my experience, the answer is almost always something, sitting there unused, because nobody ever treated it like the commercial asset it actually is.

So here's the question worth losing sleep over. If a scientist asked you for the paper behind your biggest claim tomorrow morning, what would you actually send them?